According to the US Centers for Disease Control and Prevention (NASDAQ:CDC), at least 2 million people in the United States become infected with bacteria that are resistant to antibiotics each year and at least 23,000 people die each year as a direct result of these infections. Many more people die from other conditions that were complicated by an antibiotic-resistant infection.
The rapid rise of multi-drug-resistant bacterial infections is a major global public health concern. Currently approved drugs are becoming increasingly ineffective and there are few new therapeutic agents in clinical development.
Watertown, Massachusetts-based Tetraphase Pharmaceuticals (NASDAQ:TTPH) has the opportunity to meet this umet and urgent medical need.
Would an investment in Tetraphase make a lucrative addition...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|